Clinical Trials

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03847428 2026-03-06

EMERALD-2

908 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06890598 2026-03-03

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT06992609 2026-03-02

ALBORAN

70 enrolled

Small Cell Lung Carcinoma

NCT03875235 2026-02-27

TOPAZ-1

810 enrolled 24 charts 1 FDA

Biliary Tract Neoplasms

NCT07005128 2026-02-27

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05211895 2026-02-23

PACIFIC-8

860 enrolled

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT05303532 2026-02-23

ROSY-D

214 enrolled

Tumor-Agnostic

Neoplasms

NCT05771480 2026-02-23

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT07361497 2026-02-19

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06467357 2026-02-17

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT05221840 2026-01-27

PACIFIC-9

1,051 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled

Biliary Tract Neoplasms

NCT03778957 2026-01-16

EMERALD-1

724 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06746116 2026-01-16

DUoENDE

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT03298451 2026-01-14

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Carcinoma, Hepatocellular

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Gynecologic

Endometrial Neoplasms

NCT04960709 2025-12-19

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast

Breast Neoplasms

NCT06211036 2025-12-17

DeLLphi-305

563 enrolled

Small Cell Lung Carcinoma

NCT03528694 2025-11-25

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05450692 2025-11-19

LATIFY

594 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06008093 2025-10-27

TRITON

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 2 FDA

Small Cell Lung Carcinoma

NCT04513925 2025-09-08

SKYSCRAPER-03

829 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05298423 2025-08-01

KEYVIBE-006

611 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04774380 2025-05-23

LUMINANCE

152 enrolled 17 charts

Small Cell Lung Carcinoma

NCT05043090 2025-05-08

SAMETA

148 enrolled

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05924880 2025-04-22

TopDouble

116 enrolled

Biliary Tract Neoplasms

NCT05557838 2025-02-07

TREMENDOUS

210 enrolled

Carcinoma, Hepatocellular

NCT03737643 2025-01-29

DUO-O

1,407 enrolled 2 FDA

Gynecologic

Ovarian Neoplasms

NCT05301842 2025-01-15

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04449861 2024-11-27

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

166 enrolled 20 charts